Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
Rhea-AI Summary
Oncolytics Biotech (Nasdaq: ONCY) reported voting results from its Special Meeting of Shareholders held January 15, 2026. All three resolutions passed: the Continuance (move from Alberta to British Columbia) with 14,994,075 votes for (85.21%); the Domestication (move from British Columbia to Nevada, USA) with 15,304,574 votes for (86.98%); and the 2026 Incentive Award Plan with 13,508,657 votes for (76.77%) and 4,087,822 votes against (23.23%).
The 2026 Incentive Award Plan is conditional on completion of the Continuance and Domestication. The company expects to consummate the Continuance and Domestication and for the incentive plan to become effective at the end of the first quarter of 2026.
Positive
- All three shareholder resolutions approved on January 15, 2026
- Continuance authorized: move from Alberta to British Columbia (85.21% support)
- Domestication authorized: move from British Columbia to Nevada (86.98% support)
- 2026 Incentive Award Plan approved and conditional on completion of continuance/domestication
Negative
- 2026 Incentive Award Plan had the lowest shareholder support at 76.77% (23.23% against)
- Incentive plan effectiveness is conditional and may be delayed pending completion of continuance and domestication
News Market Reaction
On the day this news was published, ATI declined 0.83%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ONCY was up 5% while close oncology peers showed mixed moves: declines in GNLX (-4.74%), ACTU (-5.23%), CRDF (-2.09%) alongside gains in HURA (5.11%) and ZURA (4.07%). This points to stock-specific strength rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Leadership appointments | Positive | +5.0% | Added senior strategy and biostatistics leaders with equity inducement awards. |
| Jan 12 | Clinical data update | Positive | +2.5% | Reported GOBLET Cohort 4 responses and duration in third-line anal cancer. |
| Jan 09 | Domestication proposal | Neutral | -2.4% | Outlined rationale and process to change jurisdiction of incorporation. |
| Jan 08 | IP strategy update | Positive | +3.2% | Detailed Track 1 patent efforts that may extend pelareorep protection to 2044. |
| Jan 07 | SAB expansion | Positive | -0.4% | Added GI tumor experts and highlighted aggregated survival and response data. |
Recent news has often been followed by positive price reactions, especially around clinical data, IP, and leadership expansion, with only one modest divergence.
Over the last weeks, Oncolytics reported several developments tied to pelareorep and corporate positioning. Management and biostatistics leadership additions on Jan 14, 2026 coincided with a 5% gain. Updated GOBLET Cohort 4 data on Jan 12 showing activity in third-line anal cancer saw shares up 2.47%. IP strategy updates on potential protection to 2044 led to a 3.23% rise. Corporate domicile and governance steps around the move to Nevada and SAB expansion drew smaller, mixed reactions, suggesting investors focus most on clinical and late-stage value drivers.
Market Pulse Summary
This announcement relates to a conference appearance and does not alter ONCY’s fundamentals. For Oncolytics, recent value drivers have centered on pelareorep clinical data, potential IP protection to 2044, and corporate steps tied to U.S. domestication and leadership expansion. With shares at $1.05, above the $0.92 200-day MA yet 30.46% below the 52-week high, investors may focus on upcoming regulatory interactions, pivotal trial plans, and execution on late-stage development milestones.
AI-generated analysis. Not financial advice.
All resolutions passed, enabling the Company to streamline regulatory and operational processes
SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Special Meeting of Shareholders (the “Special Meeting”) held on Thursday, January 15, 2026.
Each item of business described in the management information circular/prospectus of the Company dated December 9, 2025, was approved by the shareholders. The voting results for each item of business are set out below.
| Resolution | For | % | Against | % |
| Continuance Resolution | 14,994,075 | 2,602,405 | ||
| Domestication Resolution | 15,304,574 | 2,291,905 | ||
| 2026 Incentive Award Plan Resolution | 13,508,657 | 4,087,822 | ||
The approval of the first resolution authorized the Company to continue from the Province of Alberta in Canada to the Province of British Columbia in Canada (the “Continuance”). The approval of the second resolution authorized the Company to continue from the Province of British Columbia to the State of Nevada in the United States of America (the “Domestication”). The approval of the third resolution authorized the Company to implement the Oncolytics Biotech Inc. 2026 Incentive Award Plan (the “2026 Incentive Award Plan”), subject to and conditional upon the completion of the Continuance and Domestication.
The Company expects to consummate the Continuance and Domestication, and for the 2026 Incentive Award Plan to become effective at the end of the first quarter of 2026.
For more details on the matters covered at the Special Meeting, please refer to the Company’s public filings available on SEDAR+ at https://www.sedarplus.ca/home/ and on EDGAR at https://www.sec.gov/.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, of which both development programs have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding the expected consummation of the Continuance and the Domestication and effectiveness of the 2026 Incentive Award Plan, and timing thereof; and the anticipated benefits of the Continuance, Domestication, and 2026 Incentive Award Plan. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
FAQ
What shareholder votes did Oncolytics Biotech (ONCY) approve on January 15, 2026?
When will Oncolytics' 2026 Incentive Award Plan become effective for ONCY?
What were the vote tallies and percentages for ONCY's Domestication resolution?
What does the Continuance approved by ONCY shareholders involve?
How much shareholder opposition did the 2026 Incentive Award Plan face at ONCY's meeting?
